Carregant...
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
BACKGROUND: Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their met...
Guardat en:
| Publicat a: | BMC Cancer |
|---|---|
| Autors principals: | , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4237755/ https://ncbi.nlm.nih.gov/pubmed/25376790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-820 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|